20 related articles for article (PubMed ID: 18190907)
1. Sucralose, a synthetic organochlorine sweetener: overview of biological issues.
Schiffman SS; Rother KI
J Toxicol Environ Health B Crit Rev; 2013; 16(7):399-451. PubMed ID: 24219506
[TBL] [Abstract][Full Text] [Related]
2. Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women.
Lalic-Popovic M; Paunkovic J; Grujic Z; Golocorbin-Kon S; Al-Salami H; Mikov M
BMC Pregnancy Childbirth; 2013 Oct; 13():188. PubMed ID: 24134697
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract.
Limtrakul P; Khantamat O; Pintha K
Cancer Chemother Pharmacol; 2004 Dec; 54(6):525-30. PubMed ID: 15248030
[TBL] [Abstract][Full Text] [Related]
4. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
Hirai M; Tanaka K; Shimizu T; Tanigawara Y; Yasuhara M; Hori R; Kakehi Y; Yoshida O; Ueda K; Komano T
J Pharmacol Exp Ther; 1995 Oct; 275(1):73-8. PubMed ID: 7562598
[TBL] [Abstract][Full Text] [Related]
5. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
6. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms.
Li X; Li JP; Yuan HY; Gao X; Qu XJ; Xu WF; Tang W
Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):607-17. PubMed ID: 18193112
[TBL] [Abstract][Full Text] [Related]
8. Flurazepam inhibits the P-glycoprotein transport function: an insight to revert multidrug-resistance phenotype.
Lima SA; Tavares J; Gameiro P; de Castro B; Cordeiro-da-Silva A
Eur J Pharmacol; 2008 Feb; 581(1-2):30-6. PubMed ID: 18190907
[TBL] [Abstract][Full Text] [Related]
9. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.
Fox E; Bates SE
Expert Rev Anticancer Ther; 2007 Apr; 7(4):447-59. PubMed ID: 17428165
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
